NTHI

DENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding Abu Dhabi presence and high-profile banking appointment into sharper focus. The company reported that a critically ill three-year-old boy with an aggressive brain tumor is breathing independently without ventilator support and beginning to move his legs after receiving investigational intranasal NEO100 through NeOnc’s Compassionate Care program. The treatment is being administered outside the company’s pediatric clinical trial, following coordination with the child’s physicians

CALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company’s Compassionate Care program. According to his treating physicians, the patient, a critically ill three-year-old boy with an aggressive brain tumor, is now breathing independently without ventilator support and beginning to move his legs following initiation of treatment. These early observation

3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

DENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The right appointment can do more than fill a board seat. It can change a company’s public profile, open doors to new partnerships, reshape its commercial strategy and alter how investors assess its future. From Shaquille O’Neal’s involvement with Papa John’s to Elon Musk’s Twitter takeover and Donald Trump Jr.’s association with drone maker Unusual Machines, high-profile names have sometimes become catalysts for a much larger corporate story. Now, NeOnc Technologies Holdings (NASDAQ:NTHI) is making a potentially consequential move of its own with the appointment of Ali Alabedin, a senior banking executive whose international

DENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings (NASDAQ:NTHI) made a powerful leadership move at a pivotal moment in its brain-cancer drug development strategy. The appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to NeOnc’s Board of Directors. Alabedin brings more than three decades of international banking and executive experience to a company working to advance investigational therapies and expand its presence in the United Arab Emirates. FAB reported AED 1.41 trillion in total assets as of June 30, 2026, underscoring the scale of the financial institution from which NeOnc is drawing its new board-leve

CALABASAS, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer, will speak at the Abu Dhabi Future Health Summit 2026, October 20 to 22 at the ADNEC Centre in Abu Dhabi, United Arab Emirates. His participation comes as NeOnc builds its UAE clinical development presence following Department of Health – Abu Dhabi authorizations for both NEO100 and NEO212. Mr. Heshmatpour will bring the perspective of a biotechnology e

DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development progress seeks to advance treatments for some of the most difficult cancers to treat. The clinical-stage biopharmaceutical company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026, adding more than three decades of international banking, governance and business leadership experience. "Ali’s appointment strengthens our Board as we advance our clinical programs and build our presence in Abu Dhabi," said Amir Heshmatpour, NeOnc’s executive chai

CALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced the appointment of Ali Alabedin to its Board of Directors, effective October 9, 2026. Mr. Alabedin is Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), the UAE’s largest bank and a major Gulf banking institution, with AED 1.41 trillion in total assets as of June 30, 2026. The appointment brings senior banking and governance expertise to NeOnc’s Board as the Company advances its clinical programs and expands its development activities in

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A fall calendar is bringing NeOnc Technologies Holdings’ (NASDAQ:NTHI) investigational brain-cancer programs into focus. Anticipation is building as Roth Capital’s recent Buy initiation adds another Wall Street voice to the NTHI story. With Roth anticipating an October FDA discussion for NEO100 and NeOnc’s November 17 meeting for NEO212 on the calendar, the coming weeks put the company’s clinical development plans firmly in the spotlight. For traders following biotech milestones, NTHI offers a timely story to research: clinical findings, regulatory discussions and the potential next steps for two brain-cancer therapies. Oc

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ:ALEC) and NeOnc Technologies (NASDAQ:NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ:PCVX) delivers a potentially market-shifting Phase 3 vaccine readout. Alector Lands A $1.27 Billion Genentech Deal Alector (NASDAQ:ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential milestone payments of up to $1.17 billion, and tiered

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)— Today’s market is driven by an outstanding mix of listings, including Alpha Modus Holdings (NASDAQ:AMOD), Stablecoin Development (NYSEAMERICAN:SDEV), ImmunityBio (NASDAQ:IBRX), and NeOnc Technologies Holdings (NASDAQ:NTHI). Alpha Modus: Bitcoin-Fueled Balance Sheet Reset Sends Shares into Overdrive Alpha Modus (NASDAQ:AMOD) emerged as today’s most active mover, with shares surging sharply after the company closed a transaction that dramatically changes the balance-sheet story. On September 30, Alpha Modus completed a PIPE transaction in which investors delivered 3,170 bitcoin to a newly formed wholly owned subsidiary in excha

DENVER, Sept. 30, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is heading into a stretch of unusually dense catalysts, with regulatory meetings, Phase 2 readouts, potential Phase 3 transitions and blockbuster cardiometabolic data converging for NeOnc Technologies Holdings (NASDAQ:NTHI), Connect Biopharma (NASDAQ:CNTB), Valion Bio (NASDAQ:VBIO), and Eli Lilly and Company (NYSE:LLY). NeOnc: November FDA Meeting Puts NEO212 Under the Microscope NeOnc (NASDAQ:NTHI) is moving toward a potentially important regulatory checkpoint with an in-person End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration scheduled for November 17, 2026. The meeting concerns

DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotechnology market is heading into a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT), moving from promises and pipelines toward events that could materially reshape how investors view their businesses. Iovance Boosts 2026 Revenue Guidance as Amtagvi Demand Surges For Iovance (NASDAQ:IOVA), the headline is revenue. The company raised its full-year 2026 total revenue guidance to $410 million to $420 million, up $55 million at the midpoint from its previous $350 million to $370 million range. That new outlook implies nea

DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212, its oral perillyl alcohol-temozolomide conjugate being developed for aggressive central nervous system cancers. NeOnc plans to seek agency feedback on the proposed patient population, Phase 2 trial design, endpoints, dose selection and the evidence that could ultimately support a future marketing application. The company also intends to discuss po

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Kodiak Sciences (NASDAQ:KOD), NeOnc Technologies Holdings (NASDAQ:NTHI), DataMeds AI (NASDAQ:MEDS), and KNOREX (NYSEAMERICAN:KNRX) are each approaching important milestones that could reshape how investors view their pipelines, platforms and near-term prospects. Kodiak Sciences: Five Phase 3 Wins Put Zenkuda on the Regulatory Runway Kodiak Sciences (NASDAQ:KOD) delivered one of the biggest clinical updates in the group. Its pivotal Phase 3 DAYBREAK study produced positive primary-endpoint results for both Zenkuda and tabirafusp-ted in wet age-related macular degeneration. Zenkuda achieved non-inferiority to aflibercept on

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is putting another major date on the biotech calendar: November 17, 2026, when the company is scheduled to meet with the U.S. Food and Drug Administration for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212. The meeting could become an important inflection point for a company that has rapidly assembled a string of clinical, regulatory and Wall Street catalysts. NeOnc says it plans to seek FDA feedback on NEO212’s proposed patient population, trial design, endpoints, dose selection and the evidence that could ultimately support a marketi

CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212. The meeting is scheduled to take place at FDA’s White Oak campus in Silver Spring, Maryland. The Company plans to seek FDA feedback on its NEO212 clinical development program, including an update to its proposed patient population, trial design, endpoints, dose selection and evi

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- These companies are stepping into the market spotlight with very different catalysts: NeOnc (NASDAQ:NTHI) is drawing Wall Street attention around its brain-cancer pipeline and a $20 price target; Profusa (NASDAQ:PFSA) is advancing the regulatory path for its Lumee Oxygen Platform; Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) is expanding into blockchain-powered ecosystem finance through its MindWave Innovations subsidiary; and Greenland Energy Company (NASDAQ:GLND) has extended the timeline for its Jameson Land exploration program in East Greenland. NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Can

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24. The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development. The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, saying the study produ

Roth Capital initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ:NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisticated era. However, one of the field’s biggest problems remains stubbornly simple: getting effective therapy to the tumor while protecting the brain from additional damage. A July 2026 review in Science Translational Medicine described glioblastoma as remaining one of the most aggressive adult brain cancers, with survival still largely unchanged despite advances in molecular diagnostics and supportive care. At the same time, researchers are pursuing an expanding menu of approaches; targeted th